Skip to content
10-K

Annual Report

INHIBIKASE THERAPEUTICS, INC. IKT

0000950170-25-046096

← back to feed
Filed
Mar 27, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 20, 2025 74.34M sh
Revenue FY 2024 · Dec 31, 2024 $0
Revenue FY 2024 · Dec 31, 2023 $260.5K
Shares Diluted restated FY 2024 · Dec 31, 2023 6.03M sh
Capex FY 2024 · Dec 31, 2023 $14.24K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$18.09M
Cash And Equivalents restated FY 2024 · Dec 31, 2023 $9.2M
Current Liabilities FY 2024 · Dec 31, 2023 $3.44M
Total Liabilities FY 2024 · Dec 31, 2023 $3.53M
Current Assets FY 2024 · Dec 31, 2023 $14.21M
Total Assets FY 2024 · Dec 31, 2023 $14.51M
Eps Diluted restated FY 2024 · Dec 31, 2023 −$3.16
Eps Basic restated FY 2024 · Dec 31, 2023 −$3.16
Sga Expense FY 2024 · Dec 31, 2023 $6.73M
Rd Expense FY 2024 · Dec 31, 2023 $13.62M
Net Income FY 2024 · Dec 31, 2023 −$19.03M
Operating Income FY 2024 · Dec 31, 2023 −$20.09M
Stockholders Equity FY 2024 · Dec 31, 2022 $21.04M